Ultrasound contrast agent Sonazoid for the diagnosis of hepatic epithelioid angiomyolipoma: a case report

BMC Gastroenterology

Jun-yi Xin¹  Kai-yan Li¹  Zhe Huang¹ 

[1] Department of Medical Ultrasound, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, 430030, Qiaokou District, Wuhan City, Hubei Province, China;

关键词: Sonazoid;    Hepatic epithelioid angiomyolipoma;    Hepatocellular carcinoma;    Case report;   

DOI  :  10.1186/s12876-021-02064-1

来源: Springer

【 摘 要 】

BackgroundAn angiomyolipoma usually occurs in the kidneys and rarely in the liver. Hepatic epithelioid angiomyolipoma (HEAML), a rare variant of angiomyolipoma, possesses malignant potential and mimics the imaging features of hepatocellular carcinoma. Sonazoid® (perfluorobutane microbubbles), a new contrast agent that facilitates hepatic parenchyma-specific Kupffer phase imaging on contrast-enhanced ultrasonography (CEUS), is useful for the detection and characterization of focal liver lesions.Case presentationA 30-year-old man with HEAML underwent CEUS using Sonazoid®, in which new concepts for ultrasonography-based differentiation between HEAML and hepatocellular carcinoma were applied.ConclusionsThis case report provides clinicians and radiologists with a reference for distinguishing HEAML from hepatocellular carcinoma based on CEUS using Sonazoid®.

【 授权许可】

CC BY